BioBridge Global Introduces BBG Advanced Therapies: New Subsidiary to Support the Development of Cell and Gene Therapies

Leadership

Marty_sqr.jpg

Marty Landon​

Chief Executive Officer, BioBridge Global​
Dr.-Rachel-Beddard_SABJ_sqr.jpg

Rachel-Louise Beddard, MD​

Senior Vice President, Chief Medical Officer
Granville_sqr.jpg

Granville C. Betton

Senior Vice President, Talent & Performance Management
Mark-Fite_sqr.jpg

Mark Fite

Senior Vice President, BioBridge Global and Chief Operating Officer, QualTex Laboratories and GenCure
Scott_Jones_sqr.jpg

Scott Jones, PhD

Senior Vice President and Chief Scientific Officer, BioBridge Global
Adrienne_Blue_sqr.jpg

Adrienne Blevins Mendoza

Senior Vice President, BioBridge Global and Chief Operating Officer, South Texas Blood & Tissue
Richey-Wyatt_sqr.jpg

William "Richey" Wyatt

Senior Vice President, General Counsel, & Chief Compliance Officer
Youngdahl_portrait_sqr.jpg

John Youngdahl

Senior Vice President and Chief Financial Officer

Martin “Marty” Landon has more than 30 years of experience in the health care industry. Landon has held senior positions in public and private companies and is recognized for building and leading high-performance teams and value-creating initiatives. In late 2016, he joined BioBridge Global as chief executive officer where he has led both cost efficiency/productivity and revenue growth initiatives. Landon also serves as chairman of the board of Renovo Concepts Inc., an early-stage medical device company based in San Antonio, and he serves on the boards of the San Antonio Medical Foundation and BioMedSA.

Landon began his career as an internal auditor at the University of Texas Health Science Center at San Antonio and later was an auditor for four years at the international accounting firm Arthur Andersen & Co. In 1987, Landon joined lntelogic Trace, a NYSE-traded firm, where he held a number of positions with increasing levels of responsibility, including chief financial officer.

From 1994 to 2012, Landon was an executive at Kinetic Concepts Inc., now 3M, a global medical device company, where he led numerous acquisitions and financial and securities transactions. He developed major process improvements and IT initiatives that contributed to extraordinary growth, culminating in a $6.3 billion leveraged buyout. During his tenure at KCI, annual revenues increased from $250 million to nearly $2 billion.

Prior to his current role, Landon served as president and CEO of CeloNova BioSciences Inc., an early stage, innovative medical device company that develops, manufactures and sells products with multiple vascular applications. During his tenure, CeloNova completed a sale of its embolic microspheres segment to Boston Scientific.

Dr. Beddard joined South Texas Blood & Tissue Center as the VP, Medical Affairs in August 2007. Prior to joining our organization, she worked for Johns Hopkins University as an Immunology Laboratory Research Associate, Tidewater Blood Research Laboratory, as the Medical Director, and Texas Cord Blood Bank, as the Medical Director.

Dr. Beddard received her undergraduate degree from the University of Virginia and her graduate degree from Eastern Virginia Medical School. She has licensures from Virginia, Texas, Georgia, and New York. She is also board certified in Clinical Pathology and Transfusion Medicine.

Dr. Beddard was inducted into the 2023 Health Care Heroes honorees, as an outstanding physician (non-hospital based), presented by the San Antonio Business Journal.

Granville has 30 years of experience in operations, manufacturing, services, quality, safety, and process improvement and has successfully guided teams across multiple global locations, driven revenue growth and ensured excellence in service delivery.

After graduating from Rensselaer Polytechnic Institute with a Bachelor of Science in Chemical Engineering, he worked for DuPont in Delaware and Mississippi before joining GE in 1990. He spent the next 24 years in GE working in its Plastics, Medical Systems, and Silicones businesses. He held many positions with GE of increasing complexity and responsibility. In 2014 he moved to Houston TX where he worked for Nexeo Solutions, InterWrap, Inc. and Gulf Coast Regional Blood Center before joining BioBridge Global in October 2017.

Mark Fite joined BioBridge Global in July 2020. He has been Chief Operating Officer for QualTex Laboratories since June 2021 and added responsibility for GenCure in October 2022. He brings more than 30 years of wide-ranging operations experience from a variety of biomedical and pharmaceutical organizations.

Fite’s most recent role was as Chief Operating Officer at Pharmaceutical Associates Inc., a generic liquid oral dose manufacturer focused on producing generic oral dose liquid bioequivalent formulations for children, adults and the elderly who may have swallowing disorders or restricted diets. Prior to that, Fite worked for 14 years for San Antonio-based DPT Laboratories. During his tenure at DPT as Senior Vice President for Operations, he was the project leader for multiple high-impact projects that allowed DPT to grow into a premier CDMO provider.

After graduating from Appalachian State University, Fite started his career at international health and beauty aid company Revlon, and then moved on to other management roles in the United States and the United Kingdom before joining DPT.

Scott Jones, PhD became Senior Vice President and Chief Scientific Officer of BioBridge Global in October 2022. He joined BioBridge Global in 1999 and has held various positions including Director and Vice President of Laboratory Services in 2004 and 2007 and Vice President, Scientific Affairs in 2012.

Jones’ expertise includes donor screening, cell and gene therapy testing, and analytical development. His work for BioBridge Global has included the development of multiple custom assays and products for applications in advanced therapies. He also has provided support for clinical trials, especially those required for FDA approval of assays and equipment. He was an important contributor to the establishment of the organization’s cGMP cellular therapy testing services, which include development of potency assays and other applications to support advanced therapies.

He has authored and delivered numerous oral and poster presentations at annual meetings for the Association for the Advancement of Blood & Biotherapies (AABB), the Congress of International Society of Blood Transfusion, the International Society for Cell & Gene Therapy (ISCT), and Phacilitate. He is also an active member of AABB, SCABB and ISCT.

Adrienne Blevins Mendoza assumed the roles of Senior Vice President with BioBridge Global and Chief Operating Officer (COO) for South Texas Blood & Tissue in January 2022. Before this, she held the position of Vice President of Blood Operations, a role she transitioned to in December 2020 from Vice President of Global Quality at BioBridge Global. Adrienne has been a part of the BioBridge Global enterprise since 2016.

With over 25 years of experience in quality systems, regulatory affairs, Lean 6-Sigma, and strategic planning, she possesses expertise in blood and blood components, cell-based advanced therapies, and human tissue products. Adrienne completed her undergraduate studies in Business Administration at California Coast University and Biology at California State University, San Marcos. She pursued graduate studies in Administrative Leadership at the University of Oklahoma and participated in the Executive Scholars Program in Business Culture at Northwestern University’s Kellogg School of Management. She graduated with honors from the Sloan Program of Health Administration at Cornell University’s Jeb E. Brooks School of Public Policy, earning her Master of Health Administration. Additionally, she is a member of the Young American Leaders Program at Harvard Business School’s U.S. Competitiveness Project. Adrienne enjoys team building, art, music, and loves spending her free time outdoors, camping, and horseback riding.

Richey Wyatt has an extensive legal background, first as a corporate attorney with the law firm Strasburger & Price, LLP (formerly Oppenheimer, Blend, Harrison and Tate, Inc.), where he was a partner and subsequently as Sr. Vice President and General Counsel for a group of health care related entrepreneurial ventures.

Richey received his undergraduate degree from Vanderbilt University (double majoring in English & Philosophy) and his law degree, with honors, from the University of Houston Law Center. Richey is very involved in the San Antonio community having served on various community and non-profit boards as well as in Leadership San Antonio (a leadership program jointly sponsored by the San Antonio Chamber of Commerce & the San Antonio Hispanic Chamber of Commerce). Richey is married to Joan and has two sons, Henry & Taylor.

John Youngdahl became Senior Vice President and Chief Financial Officer in July 2022. Prior to that, he served as Executive Director of Finance after transitioning in September 2021 from his role as Sr. Director of FP&A. John joined BioBridge Global in December 2016 and has more than 20 years of experience holding senior financial positions in finance, including roles in operations and marketing.

John earned his Bachelor of Arts degree in finance from Gustavus Adolphus College in St. Peter, Minnesota, and an MBA from Texas State University. He is a native of Texas and has had the good fortune of spending the majority of his life in Central and South Texas.